Rituximab treatment of pemphigus foliaceus: A retrospective study of 12 patients

To the Editor: Pemphigus foliaceus (PF) is a chronic autoimmune blistering disease caused by pathogenic serum autoantibodies against desmoglein 1. Initial treatments for PF include systemic corticosteroids, immunosuppressants, and dapsone.1 Rituximab, chimeric monoclonal antibody specific to CD20 molecule on B cells, was shown be effective severe refractory cases of pemphigus in meta-analysis.2 The researchers also tried analyze efficacy this treatment PF, but results were based heterogeneous case series reports.